Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA:603392)
China · Delayed Price · Currency is CNY 30.59
-0.22 (-0.71%)
Aug 21, 2026, 3:00 PM CST
SHA:603392 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 38,678 | 56,822 | 89,141 | 95,280 | 114,799 | 134,459 | |
Market Cap Growth | -46.16% | -36.26% | -6.44% | -17.00% | -14.62% | 53.87% |
Enterprise Value | 34,867 | 52,250 | 84,105 | 90,027 | 108,497 | 134,052 |
Last Close Price | 30.59 | 44.94 | 70.46 | 74.78 | 89.12 | 107.37 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 839.09 | 76.37 | 24.24 | 66.52 |
Forward PE | - | 144.08 | 48.64 | 17.29 | 20.47 | 76.21 |
PS Ratio | 19.11 | 31.24 | 39.70 | 17.29 | 10.26 | 23.38 |
PB Ratio | 3.25 | 4.72 | 7.16 | 7.40 | 9.14 | 29.47 |
P/TBV Ratio | 3.53 | 5.13 | 7.59 | 7.82 | 9.53 | 32.20 |
P/FCF Ratio | - | - | - | 251.96 | 35.85 | 212.03 |
P/OCF Ratio | 515.82 | 633.08 | 251.04 | 61.96 | 27.78 | 79.94 |
PEG Ratio | - | 20.20 | 4.08 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 17.23 | 28.73 | 37.46 | 16.34 | 9.70 | 23.31 |
EV/EBITDA Ratio | - | - | - | 57.00 | 20.09 | 57.44 |
EV/EBIT Ratio | - | - | - | 66.00 | 20.61 | 59.91 |
EV/FCF Ratio | - | - | - | 238.07 | 33.88 | 211.39 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.06 |
Debt / EBITDA Ratio | - | - | - | 0.19 | 0.05 | 0.12 |
Debt / FCF Ratio | - | - | - | 0.82 | 0.09 | 0.45 |
Net Debt / Equity Ratio | -0.33 | -0.39 | -0.40 | -0.43 | -0.55 | -0.30 |
Net Debt / EBITDA Ratio | 10.08 | 10.52 | 96.97 | -3.52 | -1.28 | -0.59 |
Net Debt / FCF Ratio | 7.76 | 6.56 | 9.39 | -14.71 | -2.16 | -2.16 |
Asset Turnover | 0.14 | 0.13 | 0.15 | 0.35 | 0.96 | 1.09 |
Inventory Turnover | 1.37 | 1.44 | 0.98 | 1.22 | 1.64 | 1.71 |
Quick Ratio | 3.69 | 3.77 | 3.72 | 3.34 | 3.20 | 1.67 |
Current Ratio | 4.23 | 4.18 | 4.16 | 3.86 | 3.50 | 1.96 |
Return on Equity (ROE) | -3.31% | -3.38% | 0.86% | 9.80% | 56.79% | 58.22% |
Return on Assets (ROA) | -3.11% | -3.18% | -1.28% | 5.34% | 28.27% | 26.51% |
Return on Invested Capital (ROIC) | -8.71% | -9.88% | -4.23% | 18.83% | 103.82% | 79.47% |
Return on Capital Employed (ROCE) | -5.70% | -6.00% | -2.50% | 10.50% | 41.30% | 47.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.99% | -0.70% | 0.12% | 1.31% | 4.13% | 1.50% |
FCF Yield | -1.33% | -1.26% | -0.60% | 0.40% | 2.79% | 0.47% |
Dividend Yield | - | - | - | 0.43% | 0.80% | 0.09% |
Payout Ratio | - | - | 386.11% | 72.73% | 2.69% | 5.58% |
Buyback Yield / Dilution | 6.67% | 3.25% | -5.37% | -0.86% | -1.55% | -2.96% |
Total Shareholder Return | 6.67% | 3.25% | -5.37% | -0.43% | -0.75% | -2.87% |